Håkan Hedman

3.0k total citations
71 papers, 2.3k citations indexed

About

Håkan Hedman is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Håkan Hedman has authored 71 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Molecular Biology, 20 papers in Oncology and 14 papers in Immunology. Recurrent topics in Håkan Hedman's work include Glycosylation and Glycoproteins Research (27 papers), Monoclonal and Polyclonal Antibodies Research (12 papers) and Ubiquitin and proteasome pathways (10 papers). Håkan Hedman is often cited by papers focused on Glycosylation and Glycoproteins Research (27 papers), Monoclonal and Polyclonal Antibodies Research (12 papers) and Ubiquitin and proteasome pathways (10 papers). Håkan Hedman collaborates with scholars based in Sweden, France and United Kingdom. Håkan Hedman's co-authors include Roger Henriksson, Dongsheng Guo, Camilla Holmlund, Jonas Nilsson, A. Bohbot, Valérie Eschwège, Nathalie Satta, J M Freyssinet, Florence Toti and Irina Golovleva and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The EMBO Journal.

In The Last Decade

Håkan Hedman

71 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Håkan Hedman Sweden 28 1.5k 601 493 328 222 71 2.3k
Ajay K. Malik United States 10 1.1k 0.8× 590 1.0× 437 0.9× 436 1.3× 169 0.8× 16 1.8k
Christopher L. Tinkle United States 17 702 0.5× 654 1.1× 425 0.9× 496 1.5× 299 1.3× 58 1.9k
Ombretta Salvucci United States 27 919 0.6× 842 1.4× 793 1.6× 250 0.8× 139 0.6× 37 2.2k
Ann Johnsson Sweden 7 1.6k 1.1× 594 1.0× 350 0.7× 341 1.0× 193 0.9× 7 2.6k
Elina Armstrong Finland 23 1.3k 0.9× 511 0.9× 450 0.9× 198 0.6× 210 0.9× 47 2.2k
Kazuhiko Mishima Japan 27 1.2k 0.8× 1.3k 2.1× 437 0.9× 353 1.1× 662 3.0× 90 2.9k
Monica Autiero Italy 21 1.7k 1.1× 495 0.8× 352 0.7× 383 1.2× 95 0.4× 34 2.6k
Julie S. Nielsen Canada 20 686 0.5× 927 1.5× 959 1.9× 207 0.6× 138 0.6× 26 2.0k
Mario N. Lioubin United States 23 2.1k 1.4× 879 1.5× 752 1.5× 314 1.0× 140 0.6× 29 3.1k
Philip D. King United States 34 1.5k 1.0× 1.1k 1.9× 1.4k 2.9× 440 1.3× 156 0.7× 76 3.5k

Countries citing papers authored by Håkan Hedman

Since Specialization
Citations

This map shows the geographic impact of Håkan Hedman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Håkan Hedman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Håkan Hedman more than expected).

Fields of papers citing papers by Håkan Hedman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Håkan Hedman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Håkan Hedman. The network helps show where Håkan Hedman may publish in the future.

Co-authorship network of co-authors of Håkan Hedman

This figure shows the co-authorship network connecting the top 25 collaborators of Håkan Hedman. A scholar is included among the top collaborators of Håkan Hedman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Håkan Hedman. Håkan Hedman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nosek, Daniel, et al.. (2021). LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance. Oncogene. 40(21). 3707–3718. 9 indexed citations
2.
Mutie, Pascal M., Rona J. Strawbridge, Ingrid Dahlman, et al.. (2021). LRIG proteins regulate lipid metabolism via BMP signaling and affect the risk of type 2 diabetes. Communications Biology. 4(1). 90–90. 14 indexed citations
3.
Roberts, Neil, Emma Hilton, Filipa M. Lopes, et al.. (2019). Lrig2 and Hpse2, mutated in urofacial syndrome, pattern nerves in the urinary bladder. Kidney International. 95(5). 1138–1152. 28 indexed citations
4.
Thompson, Patricia A., Ingrid Ljuslinder, Spyros Tsavachidis, et al.. (2014). Loss of LRIG1 Locus Increases Risk of Early and Late Relapse of Stage I/II Breast Cancer. Cancer Research. 74(11). 2928–2935. 27 indexed citations
5.
Lindquist, David, et al.. (2014). LRIG and cancer prognosis. Acta Oncologica. 53(9). 1135–1142. 50 indexed citations
6.
Mao, Feng, Camilla Holmlund, Tommy Bergenheim, et al.. (2014). ME-12 * THE TUMOR SUPPRESSOR LRIG1 IS DOWNREGULATED BY HYPOXIA AND REGULATES GLIOBLASTOMA CELL INVASION. Neuro-Oncology. 16(suppl 5). v122–v122. 2 indexed citations
7.
Holmlund, Camilla, et al.. (2013). Lrig2-Deficient Mice Are Protected against PDGFB-Induced Glioma. PLoS ONE. 8(9). e73635–e73635. 32 indexed citations
8.
Lindquist, David, et al.. (2012). Expression of LRIG1 and LRIG3 correlates with human papillomavirus status and patient survival in cervical adenocarcinoma. International Journal of Oncology. 42(1). 247–252. 33 indexed citations
9.
Haapasalo, Hannu, Mine Eray, Katariina Korhonen, et al.. (2012). Immunohistochemical analysis of LRIG proteins in meningiomas: correlation between estrogen receptor status and LRIG expression. Journal of Neuro-Oncology. 108(3). 435–441. 11 indexed citations
10.
Wu, Xuping, Håkan Hedman, Michael Bergqvist, et al.. (2011). Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity. Acta Oncologica. 51(1). 69–76. 17 indexed citations
11.
Hedman, Håkan, Annika K. Lindström, Tibor Tot, et al.. (2010). LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix. Acta Oncologica. 49(6). 812–815. 34 indexed citations
12.
Ljuslinder, Ingrid, Irina Golovleva, Roger Henriksson, et al.. (2009). Co-incidental increase in gene copy number of ERBB2 and LRIG1 in breast cancer. Breast Cancer Research. 11(3). 403–403. 12 indexed citations
13.
Hedman, Håkan & Roger Henriksson. (2007). LRIG inhibitors of growth factor signalling – double-edged swords in human cancer?. European Journal of Cancer. 43(4). 676–682. 77 indexed citations
14.
Henriksson, Roger, et al.. (2007). Redistribution of LRIG Proteins in Psoriasis. Journal of Investigative Dermatology. 128(5). 1192–1195. 19 indexed citations
15.
Ljuslinder, Ingrid, Beatrice Malmer, Irina Golovleva, et al.. (2005). Increased copy number at 3p14 in breast cancer. Breast Cancer Research. 7(5). R719–27. 20 indexed citations
16.
Sjödin, Anna, Morten Lund‐Johansen, Bård Kronen Krossnes, et al.. (2005). Secretoglobins in the human pituitary: high expression of lipophilin B and its down-regulation in pituitary adenomas. Acta Neuropathologica. 109(4). 381–386. 12 indexed citations
17.
Holmlund, Camilla, Jonas Nilsson, Dongsheng Guo, et al.. (2004). Characterization and tissue-specific expression of human LRIG2. Gene. 332. 35–43. 63 indexed citations
18.
Hedman, Håkan, et al.. (2003). LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT–PCR and immunohistochemical analysis. British Journal of Cancer. 89(7). 1285–1289. 65 indexed citations
19.
Henriksson, Roger, Ulrika Andersson, Kjell Grankvist, et al.. (2002). Rapid Induction of Long-Lasting Drug Efflux Activity in Brain Vascular Endothelial Cells But Not Malignant Glioma Following Irradiation. Medical Oncology. 19(1). 1–10. 12 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ajay K. Malik Breakdown of academic impact, for papers by Christopher L. Tinkle Breakdown of academic impact, for papers by Ombretta Salvucci Breakdown of academic impact, for papers by Ann Johnsson Breakdown of academic impact, for papers by Elina Armstrong Breakdown of academic impact, for papers by Kazuhiko Mishima Breakdown of academic impact, for papers by Monica Autiero Breakdown of academic impact, for papers by Julie S. Nielsen Breakdown of academic impact, for papers by Mario N. Lioubin Breakdown of academic impact, for papers by Philip D. King
Rankless by CCL
2026